ABCL logo

ABCL AbCellera Biologics Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$9.69
-0.78 (-7.45%)

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under…

Market Cap: $3.16Bwww.abcellera.com

Price

$9.76+155.50%
$3.82$5.80$7.78$9.76
Apr 29Aug 11

Social Signal Score

50
5d
40
1 mentions
+0.0%
30d
53
8 mentions
+0.0%
60d
52
9 mentions
+0.0%
90d
54
12 mentions
+0.0%
news: 12

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 1Sell 0Strong Sell 0
Avg price target$18.2+87.8%
Low $9Median $18High $30
Current Consensus

Revenue

$10.64M+329.15%
$2.48M$107.18M$211.88M$316.58M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-0.58
$-0.61–$-0.54
3 analysts
FY2026
$-0.60
$-0.61–$-0.58
8 analysts
FY2027
$-0.64
$-0.72–$-0.56
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Carl Hansen
Sector
Healthcare
Industry
Biotechnology
Employees
562
Beta
1.19
Country
CA
Piotroski score
3 / 9 (Weak)
Altman Z-score
4.50
www.abcellera.com